Affinity Chromatography Matrix for Antibody Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing demand for highly purified immunoglobulin concentrates requires efficient removal of anti-A and anti-B antibodies from blood plasma, which is challenging due to the need for large donor pools with blood group O, and existing methods are not sufficiently effective in reducing these antibodies to safe levels for therapeutic use.
Innovation Solution
An affinity chromatography matrix comprising polymeric particles with oligosaccharides corresponding to blood group A and/or B epitopes grafted via a specific spacer, allowing for high selectivity and specificity in binding and removing anti-A and anti-B antibodies, thereby reducing treatment time and costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing affinity chromatography methods are used to remove anti-A and anti-B antibodies, then antibody removal is achieved, but treatment time is excessive and production costs are high
Solution Approach 1:
The patent changes the chemical parameters of the affinity matrix by using specific oligosaccharide structures (blood group A and B epitopes) with controlled density (0.1-0.5 mg/ml) and specific spacer configurations. These parameter changes optimize the binding kinetics and capacity, allowing rapid removal of anti-A and anti-B antibodies while maintaining high removal efficiency, thus resolving the contradiction between treatment time and removal efficiency.
2Reliability
If donor pools are expanded to increase blood group O availability, then antibody removal effectiveness improves, but production complexity and costs increase
Solution Approach 1:
The patent extracts the essential function of blood group O plasma (removal of anti-A and anti-B antibodies) by creating an artificial affinity matrix that mimics the antigenic properties of blood group A and B antigens. This extraction principle allows achieving the same antibody removal effectiveness without needing to expand donor pools or manage complex blood typing logistics, thus resolving the contradiction between removal effectiveness and production complexity.
3Quantity of substance
If oligosaccharide density on matrix particles is increased, then antibody binding capacity improves, but mass transfer limitations increase reducing flow rate
Solution Approach 1:
The patent applies local quality by creating a non-uniform distribution of oligosaccharides on the matrix surface through controlled grafting processes. The oligosaccharide density is optimized at 0.1-0.5 mg/ml, and the use of specific spacers (C4-C12 alkyl groups) creates local environments that facilitate both high binding capacity and good mass transfer. This localized optimization resolves the contradiction between binding capacity and flow rate by ensuring that high-density regions are strategically positioned for maximum antibody interaction while maintaining overall matrix porosity and fluid dynamics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The matrix achieves a substantial reduction in anti-A and anti-B antibodies, enabling the production of immunoglobulins with compliance to safety standards, reducing treatment time, and lowering production costs by increasing the flow rate and matrix volume, while maintaining antibody removal efficiency.
Implementation Method 1
affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A and/or group B epitope is grafted
Data Source
AI summary
The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and/or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg/ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.